Table 4.
Distribution of patients switched to second-line actinomycin D (ActD), sub-grouped according to human chorionic gonadotrophin (hCG) level. (A) <100 IU/l, (B) 100-300 IU/l, (C) 301-1000 IU/l
| FIGO score | n | Success % (n) | No. of cycles |
Relapse | |
|---|---|---|---|---|---|
| Min | Max | ||||
| A. Switch to second-line ActD, hCG <100 IU/l | |||||
| 0 | 10 | 100 (10) | 1 | 5 | |
| 1 | 12 | 100 (12) | 3 | 9 | |
| 2 | 21 | 95 (20) | 2 | 7 | 1 |
| 3 | 23 | 91 (21) | 3 | 7 | |
| 4 | 21 | 100 (21) | 3 | 6 | 2 |
| 5 | 7 | 100 (7) | 4 | 6 | |
| 6 | 2 | 100 (2) | 4 | 5 | |
| 96 | 97 (93) | 1 | 9 | 0.3% (3) | |
| B. Switch to second-line ActD, hCG 100-300 IU/l | |||||
| 0 | 3 | 66 (2) | 3 | 6 | 0 |
| 1 | 3 | 100 (3) | 5 | 7 | 0 |
| 2 | 10 | 80 (8) | 4 | 9 | 0 |
| 3 | 12 | 83 (10) | 2 | 7 | 0 |
| 4 | 7 | 100 (7) | 3 | 9 | 1 |
| 5 | 2 | 100 (2) | 6 | 6 | 0 |
| 6 | 2 | 100 (2) | 8 | 8 | 1 |
| 39 | 87 (34) | 2 | 9 | 0.5% (2) | |
| C. Switch to second-line ActD, hCG 301-1000 IU/l | |||||
| 0 | 0 | ||||
| 1 | 1 | 100 (1) | 8 | 1 | |
| 2 | 3 | 67 (2) | 3 | 7 | |
| 3 | 5 | 80 (4) | 3 | 6 | 1 |
| 4 | 6 | 83 (5) | 2 | 9 | |
| 5 | 2 | 50 (1) | 2 | 7 | |
| 6 | 0 | ||||
| 7 | 1 | 100 (1) | 9 | ||
| 18 | 78 (14) | 2 | 9 | 11% (2) | |